Article Text

Download PDFPDF

#1064 Re-hyperthermic intraoperative intraperitoneal chemotherapy (Re-HIPEC) in patients with recurrent ovarian cancer
  1. Dogan Vatansever1,
  2. Burak Giray1,
  3. Emin Erhan Donmez1,
  4. Emre Balik1,
  5. Tonguc Arslan2,
  6. Macit Arvas2 and
  7. Cagatay Taskiran1
  1. 1Koc University School of Medicine, Istanbul, Türkiye
  2. 2American Hospital, Istanbul, Türkiye


Introduction/Background The usage of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gynecological cancers is increasing. HIPEC has been widely investigated in patients with peritoneal carcinomatosis, including those with epithelial ovarian cancer. We aimed to evaluate the effects of re-HIPEC in patients with recurrent epithelial ovarian cancer who underwent re-CRS and re-HIPEC.

Methodology It was a retrospective study analyzing the patients (n=9) with advanced stage EOC undergoing HIPEC following the CRS at two tertiary hospitals.

Abstract #1064 Table 1

Results The mean age was 53.22 ± 4.68 years. The subtypes of the patients were high-grade serous cancer (n=8) and clear cell ovarian cancer (n=1) (table 1). The median recurrence time after first HIPEC was 15 (8–53, range) months. None of them developed complication during re-HIPEC.

Conclusion Re-cytoreduction with re-HIPEC is feasible and safe in recurrent ovarian cancer patients.

Disclosures All authors declare that there are no conflicts of interest involved with the presented data.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.